Zobrazeno 1 - 10
of 342
pro vyhledávání: '"A. C., Dingemans"'
Autor:
Franziska Böttger, Teodora Radonic, Idris Bahce, Kim Monkhorst, Sander R. Piersma, Thang V. Pham, Anne‐Marie C. Dingemans, Lisa M. Hillen, Mariacarmela Santarpia, Elisa Giovannetti, Egbert F. Smit, Sjaak A. Burgers, Connie R. Jimenez
Publikováno v:
Molecular Oncology, Vol 18, Iss 6, Pp 1417-1436 (2024)
The majority of patients with resected stage II‐IIIA non‐small cell lung cancer (NSCLC) are treated with platinum‐based adjuvant chemotherapy (ACT) in a one‐size‐fits‐all approach. However, a significant number of patients do not derive c
Externí odkaz:
https://doaj.org/article/59cc7532a44a481fb7f9c9573d143ffd
Autor:
Anastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, Kelly Hoefakker, Bimal Prajapati, Amrita Singh, Annemarie Boerma, Marieke van der Heiden, Sjoukje F. Oosting, Astrid A. M. van der Veldt, T. Jeroen N. Hiltermann, Corine H. GeurtsvanKessel, Anne-Marie C. Dingemans, Egbert F. Smit, Elisabeth G. E. de Vries, John B. A. G. Haanen, Pia Kvistborg, Debbie van Baarle
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionResearch has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains poorly understood.M
Externí odkaz:
https://doaj.org/article/80fab91389fd443aa2a12002abce5698
Autor:
Anyue Yin, G. D. Marijn Veerman, Johan G. C. vanHasselt, Christi M. J. Steendam, Hendrikus Jan Dubbink, Henk‐Jan Guchelaar, Lena E. Friberg, Anne‐Marie C. Dingemans, Ron H. J. Mathijssen, Dirk Jan A. R. Moes
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 4, Pp 612-623 (2024)
Abstract Insight into the development of treatment resistance can support the optimization of anticancer treatments. This study aims to characterize the tumor dynamics and development of drug resistance in patients with non‐small cell lung cancer t
Externí odkaz:
https://doaj.org/article/ea749281c095497bbf69f8fe06f78a32
Autor:
Iris G. van der Sar, Marlies S. Wijsenbeek, Gert-Jan Braunstahl, Jason O. Loekabino, Anne-Marie C. Dingemans, Johannes C. C. M. In ‘t Veen, Catharina C. Moor
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Introduction Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation. Recognition of ILD is often late, causing delay which has been associated with worse clini
Externí odkaz:
https://doaj.org/article/856fbac4a895450bbc2df9191dab5c58
Autor:
Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100656- (2024)
Introduction: Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic
Externí odkaz:
https://doaj.org/article/b8cb56c1a21d4838abe7a2a929f0a009
Autor:
Sophie M. Ernst, Maaike M. Hofman, Tessa E. van der Horst, Marthe S. Paats, Frank W.J. Heijboer, Joachim G.J.V. Aerts, Daphne W. Dumoulin, Robin Cornelissen, Jan H. von der Thüsen, Peter de Bruijn, Esther Oomen-de Hoop, Ron H.J. Mathijssen, Stijn L.W. Koolen, Anne-Marie C. Dingemans
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105074- (2024)
Summary: Background: Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, anti-PD-(L)1 concentrations, so
Externí odkaz:
https://doaj.org/article/a26effef666d4b159c43d8ae59e8c674
Autor:
Naomi C. A. van der Velden, Hanneke W. M. van Laarhoven, Sjaak A. Burgers, Lizza E. L. Hendriks, Filip Y. F. L. de Vos, Anne-Marie C. Dingemans, Joost Jansen, Jan-Maarten W. van Haarst, Joyce Dits, Ellen MA Smets, Inge Henselmans
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background For some patients with advanced cancer not knowing prognosis is essential. Yet, in an era of informed decision-making, the potential protective function of unawareness is easily overlooked. We aimed to investigate 1) the proportio
Externí odkaz:
https://doaj.org/article/6d4c5128f8fe44f6b62fc9aaba415b37
Autor:
Anita J.W.M. Brouns, Lizza E.L. Hendriks, Iris J. Robbesom-van den Berge, Annemariek J.H.M. Driessen, Guido M.J.M. Roemen, Britt L.J. van Herpen, Zoë Dekkers, Bas Heitzer, Daphne J.G. Leunissen, Laura Moonen, Ragnar Lunde, Marcel Westenend, Marjolein van Driel, Ernst-Jan M. Speel, Anne-Marie C. Dingemans
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionBone metastases are frequent in patients with non-small cell lung cancer (NSCLC). The receptor activator of Nuclear Factor κB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway is important in bone metastases development. Furthermo
Externí odkaz:
https://doaj.org/article/a528475313524589b5d2ca5c95872ab2
Autor:
Anita J.W. M. Brouns, MD, Ard van Veelen, MSc, G. D. Marijn Veerman, MD, Christi Steendam, MD, Safiye Dursun, MD, Cor van der Leest, PhD, Sander Croes, PhD, Anne-Marie C. Dingemans, MD, PhD, Lizza E.L. Hendriks, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100513- (2023)
Introduction: Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development
Externí odkaz:
https://doaj.org/article/95d916a897b6469bb454b001cdb7dbeb
Autor:
G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101955- (2023)
Summary: Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated (EGFRm+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimert
Externí odkaz:
https://doaj.org/article/3a9954ccf1454c0c889fa14273839a4e